td-0903
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 30, 2020 (NCT04350736)
Timeline
Indications
Studied for
Mechanism of action
- Tyrosine-protein kinase JAK2INHIBITOR
JAK2 inhibitor
- Jak1 proteinINHIBITOR
JAK1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05091723 | Phase 1 | Oct 13, 2021 | Theravance |
| NCT04402866 | Phase 2 | May 31, 2020 | Theravance |
| NCT04350736 | Phase 1 | Apr 30, 2020 | Theravance |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Theravance | For profit | 3 | 3 | 2 | 2020 |
1 organizations
Page 1 / 1